Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

A Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19 Study

Study Background

According to the Centers for Disease Control and Prevention, cigarette smoking causes more than 480,000 deaths each year in the United States, which translates to causing nearly one of every five deaths. Although the health impacts of smoking, such as cardiovascular and respiratory disease, cancer, and reduced fertility are well-documented, the goal of the E-Cigs and Smoking Study is to develop new biomarkers of tobacco smoke exposure or e-cigarette use. The biomarkers will be based on analysis of DNA methylation, which is the addition of methyl groups to DNA and is one of several epigenetic processes that occur in cells.

To test this hypothesis, we will establish a bank of cryopreserved peripheral blood mononuclear cells (PBMCs) from before and after COVID-19 exposure from smokers and nonsmokers and use mass cytometry (CyTOF) to analyze detailed immune profiles, test if the frequency of senescent CD8 T cells is higher among smokers who develop COVID-19 (antibody positivity) relative to those who do not develop COVID-19 positivity. To compare potential immunological biomarkers of susceptibility to viral infection with genetic, epigenetic and other biological characteristics measured in blood before and after recovery from COVID-19 illness and develop assays that indicate immune cell dysfunction and COVID-19 susceptibility.

Eligibility Criteria

  • Healthy men and women ages 30-55
  • Current cigarette or vaping users
  • No prior or current cancer diagnosis
  • A body mass index of less than 35
  • No prior history of COVID-19 infection
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Principal Investigator

Stavros Garantziotis, M.D.
Stavros Garantziotis, M.D.
Medical Director, NIEHS Clinical Research Unit
Tel 984-287-4412
Fax 919-541-9854
garantziotis@niehs.nih.gov
P.O. Box 12233
Mail Drop CU-01
Durham, N.C. 27709
Back
to Top